Remdesivir, developed by the U.S. company Gilead as a monophosphoramidate prodrug of code GS-441524 that targets viral RNA-dependent RNA polymerase is to be used on 761 patients in Wuhan, the epic center of the virus outbreak.
The medicine was intended to be an intravenous treatment for Ebola, but it also showed potential against coronavirus and Nipah virus infections.
Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal.
- Hubei Travel Memories: Three Gorges Dam
“Since these compounds have [separately] been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease,” the researchers wrote.
- Level 1 Chinese Reading Books (Journey to the West series, 600 characters)
- Level 2: Chinese Reading Books (Chinese History series, 900 characters)
- Level 3: Chinese Reading Books (Chinese Culture series, 1000 characters)
In the meanwhile, questions were raised on the patent application of the drug. How do you think? Pls send your opinions to Wuhantime. We are listening.
Will this be a turning point of the battle against the epidemic?
Source: Pengpai, SCMP, sina.com, WuhanTime.
For regular updates like us on Facebook!
If you find the write-ups useful, don’t forget to buy me a beer!
Cheers!
Last updated: Friday, February 7, 2020